Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04GWO
|
|||
| Drug Name |
Otilimab
|
|||
| Synonyms |
Otilimab [USAN]; UNII-Y8127R3VCH; Y8127R3VCH; MOR103; GSK3196165; 1638332-55-4; human monoclonal antibody
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 3 | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN colony-stimulating factor (GM-CSF) | Target Info | Inhibitor | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04333147) Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04376684) Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease. U.S. National Institutes of Health. | |||
| REF 3 | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. | |||
| REF 4 | GSK's official website (GSK3196165 otilimab) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.